0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

The N141I Mutation in PSEN2:  Implications for the Quintessential Case of Alzheimer Disease FREE

Chang-En Yu, PhD; Elizabeth Marchani, PhD; Georg Nikisch, MD; Ulrich Müller, MD; Dagmar Nolte, PhD; Andreas Hertel, MD; Ellen M. Wijsman, PhD; Thomas D. Bird, MD
[+] Author Affiliations

Author Affiliations: Geriatric Research Education and Clinical Center (Drs Yu and Bird), and Departments of Neurology (Dr Bird), and Medicine (Drs Marchani, Wijsman, and Bird), Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle; Departments of Psychiatry and Psychotherapy (Dr Nikisch) and Nuclear Medicine (Dr Hertel), Klinikum Fulda gAG, Fulda, Germany; and Institut für Humangenetik, Justus-Liebig-Universität, Giessen, Germany (Drs Nolte and Müller).


Arch Neurol. 2010;67(5):631-633. doi:10.1001/archneurol.2010.87.
Text Size: A A A
Published online

ABSTRACT

Objective  To connect a new family with early-onset Alzheimer disease (EOAD) in Germany to the American Volga German pedigrees.

Design  Pedigree molecular genetic analysis.

Setting  University Medical Centers in Fulda and Giessen, Germany, and in Seattle, Washington.

Results  The families from Fulda, Germany, and the American Volga German families with EOAD share the same N141I PSEN2 mutation on an identical haplotypic background. This establishes that the N141I mutation occurred prior to emigration of the families from the Hesse region to Russia in the 1760s, and documents that relatives of the original immigrant families are presently living in Germany with the mutation and the disease.

Conclusion  A family with the N141I mutation in PSEN2 that presently lives in Germany has been connected to the haplotype that carries the same mutation in pedigrees descended from the Volga Germans. This raises the possibility that the original patient with Alzheimer disease (Auguste D.), who had EOAD and lived in this same region of Germany, may also have had the PSEN2 N141I mutation.

Figures in this Article

In 1988, Bird and colleagues described several American pedigrees with familial early-onset Alzheimer disease (EOAD) of Volga German (VG) ancestry whose ancestors immigrated from 2 adjacent villages in Russia.1 These families share a single mutation, N141I, in the gene that encodes presenilin-2 (PSEN2; OMIM 600759).2,3 Although more than 10 additional mutations have been described in PSEN2, no families other than those of VG ancestry have been found with the N141I mutation. Recently, Nikisch et al4 described a 3-generation family in Germany with the N141I mutation. Because this family lives in the same region of Germany (Hesse) from which the VG individuals emigrated, we have performed a study attempting to link these families through shared genetic markers.

METHODS

Blood samples were obtained and DNA extracted from the American and German families with informed consent approved by the relevant institutions. Haplotype analysis of the PSEN2 region, based on multiple genetic markers, was performed on the DNA samples.

HAPLOTYPE ANALYSIS

HapMap genotype data (http://www.hapmap.org, release 22) and Haploview 4.1 software were used to assess the PSEN2 haplotype structure and to select tagging single-nucleotide polymorphisms (SNPs). Genotypes of 20 SNPs from 60 CEU singletons were downloaded and analyzed using aggressive tagging, with the linkage disequilibrium (r2) threshold set at r2 > 0.8. Six tagging SNPs (Figure) were selected, capturing all information from the original 20 SNPs. TaqMan allele discrimination assays were performed to genotype the 6 SNPs in 130 subjects from the VG pedigrees as well as in the proband with EOAD from Fulda, Germany. To extend these haplotypes to the regions flanking PSEN2, including to the more informative multiallelic short tandem repeats loci flanking PSEN2, we also genotyped D1S479, which is approximately 4 cM (1.2 megabases [Mb]) 5′ of PSEN2, and D1S225, which is approximately 1.5 cM (4.1 Mb) 3′ of PSEN2.

Place holder to copy figure label and caption
Figure.

Tagging single-nucleotide polymorphisms (SNPs) for PSEN2 haplotype analysis.

Graphic Jump Location

We used 2 strategies to estimate haplotype frequencies to accommodate data sets containing either unrelated or related individuals. We estimated SNP haplotype frequencies among 60 unrelated Centre d’Etude du Polymorphisme Humain (CEPH) Europeans using a maximum-likelihood expectation-maximization algorithm5 executed by the software package Arlequin 3.11 (http://cmpg.unibe.ch/software/arlequin3/). A single individual with missing SNP data was excluded from the haplotype estimation. Haplotype frequencies among the VGs were estimated by haplotype counting, using the SNP genotypes, pedigree information, and flanking marker data (D1S479, D1S225, N141I). Allele and haplotype counting provide unbiased estimates of allele frequencies, even in the presence of related individuals. Forced haplotypes were identified, where forced haplotypes are defined as haplotypes observed among individuals heterozygous for no more than a single SNP locus. When faced with ambiguous genotypes, we favored combinations of forced haplotypes over combinations of novel haplotypes. Haplotypes are identified by the allelic state at each of the 6 loci, in the order presented in the Figure: rs1295652, rs2073489, rs1295640, rs2236913, rs1800681, and rs2802268.

RESULTS

The Fulda (Hesse) patient had onset of memory loss at 47 years of age. Her father had onset of dementia at 64 years of age and died at 76 years. The paternal grandmother had onset at 48 years of age and died at 52 years. The American VG families have a mean age at onset of 55.5 years and mean age at death of 64 years. Not only are the onset ages similar between the VG and German families, the surname of the German family also occurs in one of the American VG families.

The genotype data for the 6 PSEN2 tagging SNPs was obtained for the CEPH and VG subjects. A total of 11 forced haplotypes were identified among the CEPH European and VG samples. The GTTACG haplotype (H1) is predominant (42%) among subjects from the VG families; this haplotype is only the fourth most frequent (13%) among the HapMap CEU sample (Table). All affected persons in the VG families share an identical PSEN2 haplotype based on these SNPs. The same haplotype was also found in the affected individual from the German family (patient III-24).

Table Graphic Jump LocationTable. Frequencies of Haplotypes and Alleles of the Markers Segregating With the N141I Mutation

The N141I mutation resides on the H1 haplotype (H1mut) shared by the affected subjects from the VG families; however, a wild-type version of the H1 haplotype (H1wt) is also present in the families in high frequency (Table). Thus, the H1mut/H1wt diplotype is common among the affected subjects in the VG families. The proband from Fulda also carries this diplotype but, because of the high frequency of the H1 haplotype, this alone is not sufficient to demonstrate shared ancestry of the VG pedigrees and the proband from Fulda. Attempts to identify additional genetic variants within this H1 haplotype group by genomic resequencing were unsuccessful, as no additional polymorphisms were identified.

To demonstrate that the proband from Fulda has the identical PSEN2 mutation haplotype as the VG families, we tested and defined subhaplotypes for the H1 haplotype group by genotyping short tandem repeats markers that flank the PSEN2 gene. Among the VG subjects, single alleles at D1S479 and D1S225 segregate with affectation status. The Table summarizes the frequencies of these alleles and the H1 SNP haplotype among genotyped VG and CEPH European subjects.

If we assume that the 2 short tandem repeats loci and haplotypes in PSEN2 are in linkage equilibrium, which is reasonable given their physical distance,6 then using the CEPH European allele frequencies, we can estimate the probability that the Fulda proband would share both risk alleles with the VG families as 0.0084. Under the assumption of linkage equilibrium among all 3 loci, the probability of the Fulda proband sharing the 2 risk alleles by chance with the VG families is between 0.1% and 0.2%, depending on whether one uses the CEPH European or the VG N141I noncarrier PSEN2 H1 haplotype frequency for estimation.

COMMENT

There are 3 interesting implications of this study. First, the N141I mutation in PSEN2 must have occurred prior to the emigration of the VGs from the Hesse region to Russia in the 1760s during the reign of Catherine the Great. Many of the immigrants assembled and then departed for Russia from the German village of Budingen, only a few kilometers from Fulda. Second, the finding of a family with this mutation living in modern Germany suggests that there are probably additional cases in Germany who share this common ancestral heritage and mutation. Third, it is of interest to note that Alois Alzheimer's original patient, Auguste D. (the quintessential case of AD), lived in the same Hesse region as the modern family, and that Auguste D. had early-onset dementia (age, 51 years).7,8 Alzheimer was working in Frankfurt (Hesse) at the time (1901). This raises the interesting possibility that Auguste D. also had the N141I mutation in PSEN2. Little is known about her family history, but her father died at the relatively young age of 45 years. Neuropathology slides from her brain have been identified, and the tissue has been tested to determine her APOE genotype (ε3/ε3), which does not contain the high-risk ε4 allele.9 It would therefore be of historical and genetic interest to determine if she carried the N141I mutation in PSEN2 because this study provides strong circumstantial evidence to support this hypothesis.

ARTICLE INFORMATION

Correspondence: Thomas D. Bird, MD, Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, University of Washington, 1660 S Columbian Way; S-182-GRECC; Seattle, WA 98108 (tomnroz@u.washington.edu).

Accepted for Publication: June 24, 2009.

Author Contributions:Study concept and design: Yu, Marchani, Müller, Wijsman, and Bird. Acquisition of data: Yu, Nolte, Hertel, and Bird. Analysis and interpretation of data: Yu, Marchani, Nikisch, Hertel, and Wijsman. Drafting of the manuscript: Yu, Marchani, Wijsman, and Bird. Critical revision of the manuscript for important intellectual content: Yu, Marchani, Nikisch, Müller, Nolte, Hertel, Wijsman, and Bird. Statistical analysis: Marchani and Wijsman. Obtained funding: Wijsman and Bird. Administrative, technical, and material support: Yu, Nolte, Hertel, Wijsman, and Bird. Study supervision: Yu, Nikisch, Müller, and Wijsman.

Financial Disclosure: Dr Bird reports receiving licensing fees and being on the Speaker's Bureau of Athena Diagnostics, Inc.

Funding/Support: This study was supported by Veterans Affairs Research funds and National Institutes of Health/National Institute on Aging grant AG005136-24.

REFERENCES

Bird  TDLampe  THNemens  EJMiner  GDSumi  SMSchellenberg  GD Familial Alzheimer's disease in American descendents of the Volga Germans: probable genetic founder effect. Ann Neurol 1988;23 (1) 25- 31
PubMed Link to Article
Levy-Lahad  EWijsman  EMNemens  E  et al.  A familial Alzheimer's disease locus on chromosome 1. Science 1995;269 (5226) 970- 973
PubMed Link to Article
Levy-Lahad  EWasco  WPoorkaj  P  et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269 (5226) 973- 977
PubMed Link to Article
Nikisch  GHertel  AKiessling  B  et al.  Three-year follow-up of a patient with early-onset Alzheimer's disease with presenilin-2 N141I mutation case report and review of the literature. Eur J Med Res 2008;13 (12) 579- 584
PubMed
Excoffier  LSlatkin  M Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12 (5) 921- 927
PubMed
Huttley  GASmith  MWCarrington  MO'Brien  SJ A scan for linkage disequilibrium across the human genome. Genetics 1999;152 (4) 1711- 1722
PubMed
Maurer  K The history of Alois Alzheimer's first case Auguste D.: how did the eponym “Alzheimer's Disease” come into being? Jucker  MBeyreuther  KHaass  CNitsch  RChristen  YAlzheimer: 100 Years and Beyond. Berlin, Germany Springer-Verlag2006;13- 34
Maurer  KVolk  SGerbaldo  H Auguste D and Alzheimer's disease. Lancet 1997;349 (9064) 1546- 1549
PubMed Link to Article
Graeber  MBKosel  SGrasbon-Frodi  EMoller  HJMehraein  P Histopathology and ApoE genotype of the first Alzheimer disease patient, Auguste D. Neurogenetics 1998;1 (3) 223- 228
Link to Article

Figures

Place holder to copy figure label and caption
Figure.

Tagging single-nucleotide polymorphisms (SNPs) for PSEN2 haplotype analysis.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable. Frequencies of Haplotypes and Alleles of the Markers Segregating With the N141I Mutation

References

Bird  TDLampe  THNemens  EJMiner  GDSumi  SMSchellenberg  GD Familial Alzheimer's disease in American descendents of the Volga Germans: probable genetic founder effect. Ann Neurol 1988;23 (1) 25- 31
PubMed Link to Article
Levy-Lahad  EWijsman  EMNemens  E  et al.  A familial Alzheimer's disease locus on chromosome 1. Science 1995;269 (5226) 970- 973
PubMed Link to Article
Levy-Lahad  EWasco  WPoorkaj  P  et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269 (5226) 973- 977
PubMed Link to Article
Nikisch  GHertel  AKiessling  B  et al.  Three-year follow-up of a patient with early-onset Alzheimer's disease with presenilin-2 N141I mutation case report and review of the literature. Eur J Med Res 2008;13 (12) 579- 584
PubMed
Excoffier  LSlatkin  M Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12 (5) 921- 927
PubMed
Huttley  GASmith  MWCarrington  MO'Brien  SJ A scan for linkage disequilibrium across the human genome. Genetics 1999;152 (4) 1711- 1722
PubMed
Maurer  K The history of Alois Alzheimer's first case Auguste D.: how did the eponym “Alzheimer's Disease” come into being? Jucker  MBeyreuther  KHaass  CNitsch  RChristen  YAlzheimer: 100 Years and Beyond. Berlin, Germany Springer-Verlag2006;13- 34
Maurer  KVolk  SGerbaldo  H Auguste D and Alzheimer's disease. Lancet 1997;349 (9064) 1546- 1549
PubMed Link to Article
Graeber  MBKosel  SGrasbon-Frodi  EMoller  HJMehraein  P Histopathology and ApoE genotype of the first Alzheimer disease patient, Auguste D. Neurogenetics 1998;1 (3) 223- 228
Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 7

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
JAMAevidence.com

Users' Guides to the Medical Literature
Clinical Resolution

Users' Guides to the Medical Literature
Clinical Scenario